

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – UPDATE ON AN INVESTIGATIONAL ONCOLOGY PRODUCT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**” or “**Lee’s Pharm**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that on 27 January 2021, the New Drug Application (“**NDA**”) of Lutrate[®] Depot (leuprolide acetate for depot suspension) 3.75 mg 1-month administration (“**Lutrate[®]**”) for the palliative treatment of advanced prostate cancer made by Lee’s Pharmaceutical (HK) Limited, a wholly-owned subsidiary of the Company, has been accepted for review by China’s National Medical Products Administration.

Lutrate[®] contains the active ingredient leuprolide acetate which belongs to a group of drugs called luteinising hormone-releasing hormone (“**LHRH**”) agonists that reduce testosterone – the major androgen. Treatment with LHRH agonists is the predominant form of androgen deprivation therapy and has become the standard of care for metastatic prostatic cancer.

According to nationwide cancer statistics using population-based cancer registry data from National Cancer Center, in males, the age-standardised incidence rate by world standard population (Segi’s population) (“**ASIRW**”) and the age-standardised mortality rate by world standard population (Segi’s population) (“**ASMRW**”) for prostate cancer increased significantly ($p < 0.05$) from 2000 to 2015. The ASIRW and ASMRW of prostate cancer in China in 2015 was about 6.47/100,000 and 2.65/100,000 respectively.

Lutrate[®] is an innovative leuprolide depot formulation licensed from GP Pharm, S.A. (“**GP Pharm**”) for the People’s Republic of China, Hong Kong, Macau and Taiwan. Lutrate[®] is currently commercialised in several countries in the EU, including Spain, Germany, Italy, Austria and Hungary among others. It is also present in Canada, as well as in some Latin America, Middle East and Asia Pacific countries.

* For identification purposes only

ABOUT GP PHARM

GP Pharm is a Spanish pharmaceutical company located in Barcelona and focused on the development, manufacture and commercialisation of high-value peptide-based injectable products some of which are based on depot formulations (microspheres and liposomes technologies). All GP Pharm's products are self-manufactured in its state-of-the-art facilities in Barcelona (Spain) and widely GMP approved by the main health authorities worldwide, including the EMA, FDA and PMDA. GP Pharm's portfolio includes prescription and hospital products in the therapeutic areas of Urology, Oncology and Women's Health. In Spain, GP Pharm promotes its branded products through its own sales force. Today, GP Pharm's products are available in more than 40 countries worldwide.

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets 23 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics and urology, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies. Lee's Pharm has also involved in the business in ophthalmology through its investment in Zhaoke Ophthalmology Limited, an associated company of the Group.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 5 February 2021

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.